Progression-free survival was significantly greater in the durvalumab plus bevacizumab group compared to placebo. 2. Common treatment-related adverse events included hypertension and anemia. Evidence ...
Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...
MedPage Today on MSN20h
NCI Flags 'Cancer Moonshot'; Dr. Hologram Will See You; Fraud Crackdown ContinuesThe American Cancer Society awarded its 2025 Medal of Honor to W. Kimryn Rathmell, MD, PhD, renowned kidney cancer expert and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback